Tokyo Tape
Sign in
← PeptiDream

Quarterly report · Q1

4587.TEDINET S100TFRV
Period2024-01-01 → 2024-03-31
Filed2024-05-15
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 48
MetricValuePeriodScopeSource row
Revenue¥4.2bn2024-01-01 → 2024-03-31Cons.Revenue IFRS
Revenue¥28.7bn2023-01-01 → 2023-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥5.0bn2023-01-01 → 2023-03-31Cons.Revenue IFRS
Operating income−¥1.1bn2024-01-01 → 2024-03-31Cons.Operating profit loss IFRS
Operating income−¥267m2023-01-01 → 2023-03-31Cons.Operating profit loss IFRS
Profit before tax−¥1.1bn2024-01-01 → 2024-03-31Cons.Profit loss before tax IFRS
Profit before tax¥4.4bn2023-01-01 → 2023-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax−¥400m2023-01-01 → 2023-03-31Cons.Profit loss before tax IFRS
Net income (owners)−¥843m2024-01-01 → 2024-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥3.0bn2023-01-01 → 2023-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)−¥249m2023-01-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income−¥843m2024-01-01 → 2024-03-31Cons.Profit loss IFRS
Net income¥3.0bn2023-01-01 → 2023-12-31Cons.Profit loss IFRS (5-year summary)
Net income−¥249m2023-01-01 → 2023-03-31Cons.Profit loss IFRS
Total assets¥69.6bnat 2024-03-31Cons.Assets IFRS
Total assets¥69.5bnat 2023-12-31Cons.Assets IFRS
Total assets¥59.8bnat 2023-03-31Cons.Total assets IFRS (5-year summary)
Total liabilities¥29.7bnat 2024-03-31Cons.Liabilities IFRS
Total liabilities¥29.1bnat 2023-12-31Cons.Liabilities IFRS
Net assets / equity¥40.0bnat 2024-03-31Cons.Equity IFRS
Net assets / equity¥40.3bnat 2023-12-31Cons.Equity IFRS
Net assets / equity¥31.8bnat 2023-03-31Cons.Equity IFRS
Net assets / equity¥32.0bnat 2022-12-31dCons.Equity IFRS
Equity (owners)¥40.0bnat 2024-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥40.3bnat 2023-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥31.8bnat 2023-03-31Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥27.3bnat 2024-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥19.5bnat 2023-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥11.6bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥5.2bnat 2022-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow−¥1.9bn2024-01-01 → 2024-03-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥12.4bn2023-01-01 → 2023-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥7.7bn2023-01-01 → 2023-03-31Cons.Net cash provided by used in operating activities IFRS
Investing cash flow¥10.4bn2024-01-01 → 2024-03-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow¥1.3bn2023-01-01 → 2023-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥381m2023-01-01 → 2023-03-31Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥757m2024-01-01 → 2024-03-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥264m2023-01-01 → 2023-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥1.1bn2023-01-01 → 2023-03-31Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥-6.52024-01-01 → 2024-03-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥23.412023-01-01 → 2023-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥-1.922023-01-01 → 2023-03-31Cons.Basic earnings loss per share IFRS
EPS (diluted)¥-6.52024-01-01 → 2024-03-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥23.382023-01-01 → 2023-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥-1.922023-01-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS
Equity ratio57.4%at 2024-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio58.1%at 2023-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio53.2%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 26
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2024-01-01 → 2024-03-31−¥75m
Reconciling Itemsreconcilingrevenue intersegment2024-01-01 → 2024-03-31−¥75m
jpcrp040300-q1r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2024-01-01 → 2024-03-31¥521m
jpcrp040300-q1r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2024-01-01 → 2024-03-31¥521m
jpcrp040300-q1r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2024-01-01 → 2024-03-31−¥955m
jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2024-01-01 → 2024-03-31¥3.8bn
jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2024-01-01 → 2024-03-31¥3.7bn
jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue intersegment2024-01-01 → 2024-03-31¥75m
jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2024-01-01 → 2024-03-31−¥121m
—segment totalrevenue2024-01-01 → 2024-03-31¥4.3bn
—segment totalrevenue external2024-01-01 → 2024-03-31¥4.2bn
—segment totalrevenue intersegment2024-01-01 → 2024-03-31¥75m
—segment totalsegment profit2024-01-01 → 2024-03-31−¥1.1bn
Reconciling Itemsreconcilingrevenue2023-01-01 → 2023-03-31−¥3m
Reconciling Itemsreconcilingrevenue intersegment2023-01-01 → 2023-03-31−¥3m
jpcrp040300-q1r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2023-01-01 → 2023-03-31¥978m
jpcrp040300-q1r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2023-01-01 → 2023-03-31¥978m
jpcrp040300-q1r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2023-01-01 → 2023-03-31−¥381m
jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2023-01-01 → 2023-03-31¥4.0bn
jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2023-01-01 → 2023-03-31¥4.0bn
jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue intersegment2023-01-01 → 2023-03-31¥3m
jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2023-01-01 → 2023-03-31¥136m
—segment totalrevenue2023-01-01 → 2023-03-31¥5.0bn
—segment totalrevenue external2023-01-01 → 2023-03-31¥5.0bn
—segment totalrevenue intersegment2023-01-01 → 2023-03-31¥3m
—segment totalsegment profit2023-01-01 → 2023-03-31−¥244m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 513
ItemContextValueUnit
Independent auditors report consolidated (text)FilingDateInstantText · Plus
Audit firm1 consolidatedFilingDateInstant
Original text (Japanese)有限責任 あずさ監査法人
Cpa1 audit firm1 consolidatedFilingDateInstant
Original text (Japanese)猪　俣　　雅　弘
Cpa2 audit firm1 consolidatedFilingDateInstant
Original text (Japanese)中　島　　悠　史
Number of submissionFilingDateInstant1
Revenue IFRS (5-year summary)Prior1YTDDuration4963470000JPY
Revenue IFRS (5-year summary)CurrentYTDDuration4225166000JPY
Revenue IFRS (5-year summary)Prior1YearDuration28712194000JPY
Profit loss before tax IFRS (5-year summary)Prior1YTDDuration-399914000JPY
Profit loss before tax IFRS (5-year summary)CurrentYTDDuration-1104054000JPY
Profit loss before tax IFRS (5-year summary)Prior1YearDuration4353469000JPY
Profit loss attributable to owners of parent IFRS (5-year summary)Prior1YTDDuration-248801000JPY
Profit loss attributable to owners of parent IFRS (5-year summary)CurrentYTDDuration-842543000JPY
Profit loss attributable to owners of parent IFRS (5-year summary)Prior1YearDuration3035832000JPY
Profit loss IFRS (5-year summary)Prior1YTDDuration-248801000JPY
Profit loss IFRS (5-year summary)CurrentYTDDuration-842543000JPY
Profit loss IFRS (5-year summary)Prior1YearDuration3035832000JPY
Comprehensive income attributable to owners of parent IFRS (5-year summary)Prior1YTDDuration-234467000JPY
Comprehensive income attributable to owners of parent IFRS (5-year summary)CurrentYTDDuration-373094000JPY
Comprehensive income attributable to owners of parent IFRS (5-year summary)Prior1YearDuration8760519000JPY
Comprehensive income IFRS (5-year summary)Prior1YTDDuration-234467000JPY
Comprehensive income IFRS (5-year summary)CurrentYTDDuration-373094000JPY
Comprehensive income IFRS (5-year summary)Prior1YearDuration8760519000JPY
Equity attributable to owners of parent IFRS (5-year summary)Prior1QuarterInstant31812012000JPY
Equity attributable to owners of parent IFRS (5-year summary)CurrentQuarterInstant39984726000JPY
Equity attributable to owners of parent IFRS (5-year summary)Prior1YearInstant40349709000JPY
Total assets IFRS (5-year summary)Prior1QuarterInstant59776628000JPY
Total assets IFRS (5-year summary)CurrentQuarterInstant69637141000JPY
Total assets IFRS (5-year summary)Prior1YearInstant69464013000JPY
Basic earnings loss per share IFRS (5-year summary)Prior1YTDDuration-1.92
Basic earnings loss per share IFRS (5-year summary)CurrentYTDDuration-6.50
Basic earnings loss per share IFRS (5-year summary)Prior1YearDuration23.41
Diluted earnings loss per share IFRS (5-year summary)Prior1YTDDuration-1.92
Diluted earnings loss per share IFRS (5-year summary)CurrentYTDDuration-6.50
Diluted earnings loss per share IFRS (5-year summary)Prior1YearDuration23.38
Ratio of owners equity to gross assets IFRS (5-year summary)Prior1QuarterInstant0.532
Ratio of owners equity to gross assets IFRS (5-year summary)CurrentQuarterInstant0.574
Ratio of owners equity to gross assets IFRS (5-year summary)Prior1YearInstant0.581
Cash flows from used in operating activities IFRS (5-year summary)Prior1YTDDuration7737043000JPY
Cash flows from used in operating activities IFRS (5-year summary)CurrentYTDDuration-1923059000JPY
Cash flows from used in operating activities IFRS (5-year summary)Prior1YearDuration12420969000JPY
Cash flows from used in investing activities IFRS (5-year summary)Prior1YTDDuration-380637000JPY
Cash flows from used in investing activities IFRS (5-year summary)CurrentYTDDuration10395130000JPY
Cash flows from used in investing activities IFRS (5-year summary)Prior1YearDuration1302539000JPY
Cash flows from used in financing activities IFRS (5-year summary)Prior1YTDDuration-1140441000JPY
Cash flows from used in financing activities IFRS (5-year summary)CurrentYTDDuration-757399000JPY
Cash flows from used in financing activities IFRS (5-year summary)Prior1YearDuration264191000JPY
Cash and cash equivalents IFRS (5-year summary)Prior1QuarterInstant11626423000JPY
Cash and cash equivalents IFRS (5-year summary)CurrentQuarterInstant27335184000JPY
Cash and cash equivalents IFRS (5-year summary)Prior1YearInstant19507861000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-12-31pass rounding
balance sheet identityconsolidated 2024-03-31pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-03-31pass
statement vs summary · net income attributable to parentconsolidated 2024-01-01/2024-03-31pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-03-31pass
statement vs summary · operating cash flowconsolidated 2024-01-01/2024-03-31pass
statement vs summary · revenueconsolidated 2023-01-01/2023-03-31pass
statement vs summary · revenueconsolidated 2024-01-01/2024-03-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass
statement vs summary · total assetsconsolidated 2024-03-31pass